Abstract 462P
Background
The aim of this study was to identify correlates of cognitive function among cancer survivors attending rehabilitation in a community setting.
Methods
Participants were 35 cancer patients who had reported memory issues and were screened by an occupational therapist for cognitive dysfunction. Using baseline data, descriptive and bivariate analyses were performed to detail the cognitive function of study sample and to identify its correlates.
Results
Study sample was predominantly female (94.7%) with breast cancer (65.8%) who had received chemotherapy (77.1%) and hormonal therapy (51.5%). Mean age was 53.8 ± 10.3 years and mean years since diagnosis was 4.9 ± 3.3 years. Mean scores of cognitive performances were within the norms for attention (digit span forward test; 7.5 ± 1.4), working memory (digit span backward test; 5.4 ± 1.3), processing speed (trail making test A; 25.1 ± 5.5), and executive function (trail making test B; 68.3 ± 33.6). Mean scores of perceived cognitive ability (15.5 ± 4.1) and cognitive-related quality of life (9.8 ± 3.7), measured by the FACT-Cog, were below the norms. Cancer survivors with more years since diagnosis performed better in executive function (r = .45). Poorer working memory (r = -.38) and lower cognitive-related quality of life (r = -.41) were also found to associate with increased fatigue intensity. Although sleep duration and distress rating were not related to cognitive function, shorter sleep duration (r = -.35) and higher distress rating (r = .37) correlated with higher fatigue intensity. All results were statistically significant at p < 0.05.
Conclusions
Cancer survivors may report reduced perceived cognitive ability and cognitive-related quality of life despite adequate performance on objective tests. This discrepancy could be due to the relationship of fatigue to working memory. Global evaluation of cognitive function considers cognitive performance during periods of more intense fatigue while objective tests provide information on cognitive performance when tested at a particular time and fatigue level. Managing fatigue including addressing distress and sleep issues may be potential strategies that can be employed to support cognitive function.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
581P - The associations between afatinib-related adverse events and survival outcomes in patients with lung cancer
Presenter: Wen-Chen Tang
Session: Poster Display
Resources:
Abstract
582P - Furmonertinib treatment in patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastases: A real-world study
Presenter: Haiyang Chen
Session: Poster Display
Resources:
Abstract
583P - RHBDL2 promotes non-small cell lung cancer metastasis and osimertinib resistance by activating the RAS/MEK/ERK signaling pathway through interaction with FGFR
Presenter: jun Deng
Session: Poster Display
Resources:
Abstract
584P - Upfront aumolertinib for preventing symptomatic central nervous system(CNS) metastases in EGFR-mutant non-small cell lung cancer without baseline CNS metastasis
Presenter: Tangfeng Lv
Session: Poster Display
Resources:
Abstract
585P - Real-world outcomes in patients with non-small cell lung cancer with EGFR exon 20 insertion mutations receiving mobocertinib
Presenter: Tony S.K. Mok
Session: Poster Display
Resources:
Abstract
586P - Clinical validation of a multiplex polymerase chain reaction (mPCR) assay to identify patients (pts) with NSCLC suitable for mobocertinib treatment
Presenter: Caicun Zhou
Session: Poster Display
Resources:
Abstract
587P - Exploring the prevalence and characteristics of human epidermal growth factor receptor 2 (HER2) alterations in non-small cell lung cancer: Analysis from a Malaysian cohort
Presenter: Ning Yi Yap
Session: Poster Display
Resources:
Abstract
588P - First real-world study with HER2 ADC in treating HER2-altered non-small cell lung cancer
Presenter: Kaihua Lu
Session: Poster Display
Resources:
Abstract
590P - A retrospective study of the prevalence and clinical outcomes of KRAS G12C mutated advanced non-small cell lung cancer (NSCLC) in Australian patients (pts)
Presenter: Ben Markman
Session: Poster Display
Resources:
Abstract
591P - The utility of next generation sequencing for KRAS gene variants prevalence in cytological and tissue samples in real-world NSCLC patients: A large single institution real-world study
Presenter: Adam Pluzanski
Session: Poster Display
Resources:
Abstract